Response from the international transporter consortium

Nature Reviews Drug Discovery

Volumn 10, Issue 1, 2011, Pages 75-

  Lee, Caroline A ^a   Hillgren, Kathleen M ^b   Zhang, Lei ^c   Polli, Joseph W ^d  

^a PFIZER INC   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; ERYTHROMYCIN; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; KETOCONAZOLE; MACROGOL; PROPYLENE GLYCOL; QUINIDINE; RIFAMPICIN; TALINOLOL;

AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG FORMULATION; DRUG LABELING; DRUG SOLUBILITY; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HUMAN; LETTER; MAXIMUM PLASMA CONCENTRATION; MOLECULAR PROBE; PRIORITY JOURNAL; TABLET FORMULATION;

EID: 78650844924     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3028-c2     Document Type: Letter

References (21)

1. The International Transporter Consortium. Membrane transporters in drug development. Nature Rev. Drug Discov. 9, 215- 236 (2010).
2. Shi, J. G., Zhang, Y. & Yeleswaram, S. The relevance of assessment of intestinal P-gp inhibition using digoxin as an in vivo probe substrate. Nature Rev. Drug Discov. 31 Dec 2010 (doi:10.1038/nrd3028-c1).
3. American Society of Health-System Pharmacists. Digoxin oral products [online], http://www.ashp.org/ Import/PRACTICEANDPOLICY/PracticeResource Centers/DrugShortages/GettingStarted/ ResolvedShortages/bulletin.aspx?id=405, 2009.
4. Keogh, J. P. & Kunta, J. R. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. Eur. J. Pharm. Sci. 27, 543-554 (2006).
5. Drescher, S. et al. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin. Pharmacol. Ther. 73, 223-231 (2003).
6. Greiner, B. et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104, 147-153 (1999).
7. Eichelbaum, M. et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 1 1 0, 571 (2002).
8. Fenner, K. S. et al. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro- in vivo correlation using digoxin as a probe drug. Clin. Pharmacol. Ther. 85, 173-181 (2009).
9. Boyd, R. A. et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J. Clin. Pharmacol. 40, 91-98 (2000).
10. De Mey, C., Brendel, E. & Enterling, D. Carvedilol increases the systemic bioavailability of oral digoxin. Br. J. Clin. Pharmacol. 29, 486-490 (1990).
11. Robinson, K. et al. The digoxin-amiodarone interaction. Cardiovasc. Drugs Ther. 3, 25-28 (1989).
12. Rodin, S. M., Johnson, B. F., Wilson, J., Ritchie, P. & Johnson, J. Comparative effects of verapamil and isradipine on steady-state digoxin kinetics. Clin. Pharmacol. Ther. 43, 668-672 (1988).
13. Parker, R. B., Yates, C. R., Soberman, J. E. & Laizure, S. C. Effects of grapefruit juice on intestinal P-glycoprotein: evaluation using digoxin in humans. Pharmacotherapy 23, 979-987 (2003).
14. Ohnishi, A. et al. Effect of furanocoumarin derivatives in grapefruit juice on the uptake of vinblastine by Caco-2 cells and on the activity of cytochrome P450 3A4. Br. J. Pharmacol. 130, 1369-1377, (2000).
15. de Castro, W. V., Mertens-Talcott, S., Derendorf, H. & Butterweck, V. Grapefruit juice-drug interactions: Grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells. J. Pharm. Sci. 96, 2808-2817 (2007).
16. Dahan, A. & Amidon, G. L. Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein. Pharm. Res. 26, 883-892 (2009).
17. Chin, T. W., Loeb, M. & Fong, I. W. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob. Agents Chemother. 39, 1671-1675 (1995).
18. Hurwitz, A., Ruhl, C. E., Kimler, B. F., Topp, E. M. & Mayo, M. S. Gastric function in the elderly: effects on absorption of ketoconazole. J. Clin. Pharmacol. 43, 996-1002 (2003).
19. Schwarz, U. I., Gramatte, T., Krappweis, J., Oertel, R. & Kirch, W. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int. J. Clin. Pharmacol. Ther. 38, 161-167 (2000).
20. Westphal, K. et al. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin. Pharmacol. Ther. 68, 345-355 (2000).
21. Toffoli, G. et al. Structure-activity relationship of verapamil analogs and reversal of multidrug resistance. Biochem. Pharmacol. 50, 1245-1255 (1995).